
    
      Patients with confirmed dengue fever who meet all inclusion and exclusion criteria will be
      enrolled and admitted to the Investigational Medicine Unit. Patients will be randomized 1:1
      to celgosivir or placebo. Capsules of placebo or celgosivir will be administered for 5 days.
      While in hospital, daily clinical exams will be conducted, and blood samples will be
      collected for viral load, quantitative NS1, hematology, clinical chemistry, cytokine levels
      and pharmacokinetics (PK). Safety assessments will be conducted. At discharge on Study Day 5,
      patients will be asked to return on Study Days 7, 10, and 15 for blood sampling and safety
      assessments.
    
  